BridgeBio Pharma, Inc.
BBIO · Healthcare
$76.57
Φόρτωση γραφήματος…
Νέα
Τελευταίοι τίτλοι για αυτή τη μετοχή
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
BioMarin settled a patent dispute with Ascendis Pharma over the achondroplasia drug Yuviwel, converting a competitive threat into a royalty stream. Under the agreement, BioMarin will receive 20% royalties on U.S. Yuviwel sales and 18% in the EU, Brazil, and South Korea through May 2030. While this monetizes competition, BioMarin still faces market pressure from Yuviwel and potential future competitors like BridgeBio's infigratinib.
BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
BridgeBio Pharma has entered into a voluntary agreement with the U.S. government to expand Medicaid access to its marketed medicine Attruby and lower drug costs for American patients. The agreement includes expanded state Medicaid access via the GENEROUS Model and maintains the company's ForgingBridges patient assistance program. BridgeBio expects not to be subject to future pricing mandates under this arrangement.
BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher.
BridgeBio Pharma's stock has surged 29% in three months, driven by strong performance of its FDA-approved heart medication Attruby, which saw sales more than triple year-over-year to $222 million in Q2. With 16 out of 17 analysts recommending a buy and three promising drugs in late-stage development under FDA review, Wall Street believes the stock has further upside potential despite the company remaining unprofitable.